Small, dense low density lipoprotein (sdLDL) represents an emerging cardiovascular risk
factor, since these particles can be associated with cardiovascular disease (CVD) …

The focus of this review is on the role of apolipoprotein C-II (apoC-II) in lipoprotein
metabolism and the potential effects on the risk of cardiovascular disease (CVD). We …

Aim of the present Consensus Statement is to provide a comprehensive and up to-date
document on the pathophysiology, atherogenicity and clinical significance of low density …

Ezetimibe is a cholesterol absorption inhibitor that blocks the intestinal absorption of both
biliary and dietary cholesterol. It appears to exert its effect by blocking intestinal sterol …

Rheumatoid arthritis (RA) associates with excess cardiovascular morbidity and mortality,
resulting in significantly shortened lifespan. Traditional risk factors (eg dyslipidaemia and …

Background: Patients with diabetes usually exhibit diabetic dyslipidaemia. Aim: The aim of
the review is to present the quantitative and qualitative alterations of lipids and lipoproteins …

Spirulina platensis is a blue-green algae with potential anti-obesity effects. In this study, the
anti-obesity effects of whole Spirulina platensis (WSP), Spirulina platensis protein (SPP) and …

Background: Increasing evidence suggest that the 'quality'rather than only the 'quantity'of
low‐density lipoprotein (LDL) exerts a great influence on the cardiovascular risk. Small …

Dyslipidaemia is frequently present in obesity, metabolic syndrome (MetS) and type 2
diabetes mellitus (T2DM). The predominant features of dyslipidaemia in these disorders …

Metabolic syndrome (MetS), a cluster of dyslipidaemia, central obesity, hypertension and/or
insulin resistance, is associated with increased cardiovascular disease (CVD) type 2 …